产品说明书

	同义名 :	AM-1155 sesquihydrate;BMS-206584 sesquihydrate;PD135432 sesquihydrate
	CAS号 :	180200-66-2
	货号 :	A152235
	分子式 :	C38H50F2N6O11
	纯度 :	95%
	分子量 :	804.83
	MDL号 :	MFCD22373645
	存储条件：	粉末 Inert atmosphere,Room Temperature 液体 -20°C:3-6个月-80°C:12个月
	溶解度 :	-
	动物实验配方：

生物活性

描述

Gatifloxacin (Sesquihydrate) is an antibiotic of the fourth-generation fluoroquinolone family. Ophthalmic gatifloxacin 0.3% is at least as effective as ciprofloxacin at healing corneal ulcers infected with Pseudomonas aeruginosa when gatifloxacin is administered less frequently than ciprofloxacin[3]. Gatifloxacin possessed potent activity (MIC, 0.39 microg/ml) against the NorA-overproducing strain S. aureus NY12, the norA transformant, which was slightly lower than that against the parent strain SA113[4]. Ocular inserts of gatifloxacin were prepared successfully by using solvent casting method for sustained drug delivery. The cross-linked and Eudragit RL-100 coated ocular insert of gatifloxacin provides better in vitro drug release and sustained upto 11h[2].

实验方案
	1mg	5mg	10mg
1 mM 5 mM 10 mM	1.24mL 0.25mL 0.12mL	6.21mL 1.24mL 0.62mL	12.42mL 2.48mL 1.24mL

参考文献

[1]Pantel A, Petrella S, et al. Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis. Antimicrob Agents Chemother. 2012 Apr;56(4):1990-6. [2]Khurana G, Arora S, Pawar PK. Ocular insert for sustained delivery of gatifloxacin sesquihydrate: Preparation and evaluations. Int J Pharm Investig. 2012;2(2):70–77 [3]Jensen H, Zerouala C, Carrier M, Short B. Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits. J Ocul Pharmacol Ther. 2005;21(1):36–43 [4]Fukuda H, Hori S, Hiramatsu K. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus. Antimicrob Agents Chemother. 1998;42(8):1917–1922